REG-Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
Key Highlights
- ➤Petrelintide cut mean body weight up to 9.2% at week 28 versus 2.0% placebo
- ➤HbA1c fell up to 0.65% versus a 0.23% increase with placebo
- ➤Gastrointestinal discontinuations remained low at 1.9% versus 1.7% for placebo
- ➤Zealand Pharma and Roche launched Phase 3a program targeting approximately 7,000 participants
- ➤Phase 3a trials evaluate petrelintide across obesity, type 2 diabetes, and cardiovascular disease populations
Expert Statements
David Kendall, Chief Medical Officer at Zealand Pharma
“These results further support the potential of petrelintide in chronic weight management and, for the first time, demonstrate its promise as a standalone treatment for those living with overweight or obesity and type 2 diabetes.”
David Kendall, Chief Medical Officer at Zealand Pharma
“These data confirm the potential for clinically meaningful weight reduction with a promising and favorable tolerability profile.”
David Kendall, Chief Medical Officer at Zealand Pharma
“We are also encouraged by the improvements in glycemic control - a combination essential for supporting long-term, sustained benefits in people living with obesity and type 2 diabetes.”
David Kendall, Chief Medical Officer at Zealand Pharma
“Together with Roche, we look forward to investigating petrelintide in our recently initiated Phase 3 registrational program to address important unmet medical needs in chronic weight management.”
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes * Petrelintide achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo * At week 28, petrelintide demonstrated a HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo * Safety and tolerability profile of petrelintide was consistent with that seen in the Phase 2 ZUPREME-1 trial * Very low discontinuation rates due to gastrointestinal adverse events (1.9% for petrelintide versus 1.7% in placebo group) * Data reinforce potential of petrelintide as a future first choice therapy for chronic weight management Copenhagen, Denmark, October 7, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced positive topline results from the Phase 2 ZUPREME-2 trial evaluating the efficacy and safety of petrelintide versus placebo in 220 people living with overweight or obesity and type 2 diabetes (mean baseline BMI of 36.3 kg/m(2); mean baseline HbA1c of 8.0%).
Get started
Create a free account to read the full story.